Key result
Impella increases thrombosis risk ~394% in cardiogenic shock, with bleeding rates between IABP and ECMO.
Why the study?
Mortality remains high in myocardial infarction complicated by cardiogenic shock, and mixed study results limit adoption of Impella despite its hemodynamic benefits.
Does Impella improve mortality and clinical events compared to IABP or ECMO in patients with myocardial infarction complicated by cardiogenic shock?
Does Impella improve mortality and clinical events compared to IABP or ECMO in patients with myocardial infarction complicated by cardiogenic shock?
In patients with MI complicated by cardiogenic shock, Impella use is associated with higher thrombosis and bleeding risks compared to IABP, but lower bleeding risk than ECMO, without significant differences in other outcomes.
Consider thrombosis and bleeding risks in MCS device selection for cardiogenic shock; extends comparative safety data from mixed prior evidence.
Despite technological advancements, mortality remains high in patients with myocardial infarction complicated by cardiogenic shock. Impella is increasingly used as an adjunct to standard treatment due to its hemodynamic benefits, though mixed study results limit its adoption. This meta-analysis aims to clarify Impella’s efficacy by focusing on high-quality data from RCTs and cohort studies. A comprehensive literature search was conducted for randomized controlled trials and cohort studies comparing Impella with intra-aortic balloon pump (IABP) and extracorporeal membrane oxygenation (ECMO). Assessed metrics included mortality, clinical events, and hematologic markers. Data was analyzed using the Mantel-Haenszel random-effects model. Of 787 articles, 12 studies (4918 patients) met the inclusion criteria. Impella groups showed significant increases in thrombosis risk (RR: 4.94) and had a higher bleeding risk compared to IABP (RR: 1.98) but a lower risk compared to ECMO (RR: 0.66). All other comparisons did not reach statistical significance. Despite updated data and a stringent quality threshold, the hemodynamic benefits of Impella and the device’s risk of thrombosis and bleeding were high. Future trials should emphasize patient selection, timing of placement, and operator proficiency to evaluate Impella’s efficacy and safety better.
No takes yet. Share an insight, caveat, or question.
Berry et al. (2026) studied this question. Impella significantly increases thrombosis risk (RR 4.94) and has higher bleeding risk than IABP (RR 1.98) but lower bleeding risk than ECMO (RR 0.66) in cardiogenic shock.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: